ES2192667T3 - Tratamiento de los trastornos de la artritis, artritis reumatica y manifestaciones asociadas con los trastornos reumaticos. - Google Patents
Tratamiento de los trastornos de la artritis, artritis reumatica y manifestaciones asociadas con los trastornos reumaticos.Info
- Publication number
- ES2192667T3 ES2192667T3 ES97906339T ES97906339T ES2192667T3 ES 2192667 T3 ES2192667 T3 ES 2192667T3 ES 97906339 T ES97906339 T ES 97906339T ES 97906339 T ES97906339 T ES 97906339T ES 2192667 T3 ES2192667 T3 ES 2192667T3
- Authority
- ES
- Spain
- Prior art keywords
- arthritis
- disorders
- treatment
- syndrome
- manifestations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE AL USO DE INHIBIDORES FARMACEUTICAMENTE ACEPTABLES DE LA COLINESTERASA PARA LA PREPARACION DE UNA COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO O PROFILAXIS DE LOS TRASTORNOS ARTRITICOS, INCLUIDOS LA OSTEOARTRITIS, LA ARTRITIS REUMATOIDE Y OTRAS ENFERMEDADES REUMATOIDES TALES COMO LA ARTRITIS JUVENIL, EL LUPUS ERITEMATOSO SISTEMICO, EL SINDROME DE SJOGREN, LA ESCLEROSIS SISTEMICA PROGRESIVA, LA POLIMIOSITIS, LA DERMATOMIOSITIS, LA ESPONDILITIS ANQUILOSANTE, EL SINDROME DE REITER, LA ARTRITIS PSORIATICA, LA POLICONDRITIS RECIDIVA, LA PANNICULITIS CON RECIDIVA, LA ENFERMEDAD DE CROHN, LA COLITIS ULCERATIVA, LAS DEFICIENCIAS HEREDITARIAS DEL COMPLEMENTO, LAS ENFERMEDADES VASCULARES DEL COLAGENO, EL SINDROME DE FELTY, LAS MANIFESTACIONES REUMATOLOGICAS ASOCIADAS A ENDOCARDITIS O MIOCARDITIS BACTERIANAS Y VIRALES Y OTRAS MANIFESTACIONES REUMATOLOGICAS, TALES COMO LA ANEMIA POR TRASTORNOS CRONICOS. LA INVENCION SE REFIERE IGUALMENTE A UN NUEVO PROCEDIMIENTO DE TRATAMIENTO O PROFILAXIS DE ESTAS ENFERMEDADES Y MANIFESTACIONES. LOS INHIBIDORES DE LA COLINESTERASA SE SELECCIONAN PREFERENTEMENTE DE UN GRUPO DE INHIBIDORES NICOTINICOS DE LA ACETILCOLINESTERASA, COMO LA GALANTAMINA (ESTE FARMACO SE DENOMINABA ANTERIORMENTE GALANTHAMINA).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IS4325 | 1996-02-19 | ||
GBGB9606736.8A GB9606736D0 (en) | 1996-02-19 | 1996-03-29 | Therapeutic method |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2192667T3 true ES2192667T3 (es) | 2003-10-16 |
Family
ID=36764777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES97906339T Expired - Lifetime ES2192667T3 (es) | 1996-02-19 | 1997-02-19 | Tratamiento de los trastornos de la artritis, artritis reumatica y manifestaciones asociadas con los trastornos reumaticos. |
Country Status (11)
Country | Link |
---|---|
US (1) | US6358941B1 (es) |
EP (1) | EP0918523B1 (es) |
AT (1) | ATE232102T1 (es) |
AU (1) | AU2105997A (es) |
CA (1) | CA2251114C (es) |
DE (1) | DE69718915T2 (es) |
DK (1) | DK0918523T3 (es) |
ES (1) | ES2192667T3 (es) |
GB (1) | GB9606736D0 (es) |
HK (1) | HK1020535A1 (es) |
WO (1) | WO1997029750A1 (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999008672A1 (en) * | 1997-08-15 | 1999-02-25 | Shire International Licensing Bv | Use of cholinesterase inhibitor for treating diseases associated with proteolytic enzyme activity |
US6193993B1 (en) | 1998-03-03 | 2001-02-27 | Eisai Co., Ltd. | Suppository containing an antidementia medicament |
IT1304904B1 (it) * | 1998-09-11 | 2001-04-05 | Eisai Co Ltd | Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche |
US20030224071A1 (en) * | 1999-08-20 | 2003-12-04 | Howard Murad | Pharmaceutical compositions and methods for managing connective tissue ailments |
US20050063998A1 (en) * | 1999-10-26 | 2005-03-24 | Francois Marc Karel Jozef | Oral solution containing galantamine and a sweetening agent |
CA2310950C (en) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | An efficacious dosage regiment of galantamine that reduces side effects |
US7226916B1 (en) * | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
ES2427930T3 (es) | 2001-05-23 | 2013-11-04 | Mitsubishi Tanabe Pharma Corporation | Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos |
WO2002094321A1 (fr) | 2001-05-23 | 2002-11-28 | Tanabe Seiyaku Co., Ltd. | Compositions favorisant la guérison d'une fracture osseuse |
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
US20050048543A1 (en) * | 2003-07-11 | 2005-03-03 | Jeroen Aerssens | CHRNA2 genetic markers associated with galantamine response |
DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
US20050260613A1 (en) * | 2003-10-28 | 2005-11-24 | Genaissance Pharmaceuticals | LRPAP1 genetic markers associated with galantamine |
US7250258B2 (en) * | 2003-12-15 | 2007-07-31 | Pgxhealth Llc | CDK5 genetic markers associated with galantamine response |
WO2005065661A2 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Immediate, controlled and sustained release formulations of galanthamine |
WO2005065662A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Solid dosage formulations of galantamine |
EP2518510A1 (en) * | 2004-04-20 | 2012-10-31 | SphingoTec GmbH | Use of precursors of tachykinins and/or their fragments in medical diagnostic |
US9132135B2 (en) * | 2004-09-24 | 2015-09-15 | University Of Maryland, Baltimore | Method of treating organophosphorous poisoning |
WO2006036686A2 (en) * | 2004-09-24 | 2006-04-06 | University Of Maryland, Baltimore | Method of treating organophosphorous poisoning |
EP1807087A2 (en) | 2004-10-12 | 2007-07-18 | Ernir Snorrason | Inhibitors of acetylcholinesterase for treating skin diseases |
US8193212B2 (en) * | 2005-05-23 | 2012-06-05 | President And Fellows Of Harvard College | Use of huperzine for neuropathic pain |
CN101190330A (zh) * | 2006-11-30 | 2008-06-04 | 深圳市鼎兴生物医药技术开发有限公司 | 胆碱酯酶在拮抗速激肽药物中的应用 |
FR2912841B1 (fr) * | 2007-02-15 | 2009-05-22 | Soitec Silicon On Insulator | Procede de polissage d'heterostructures |
WO2009151634A1 (en) * | 2008-06-12 | 2009-12-17 | The Board Of Trustees Of The Leland Stanford Junior University | Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis |
CA2736114A1 (en) * | 2008-09-04 | 2010-03-11 | President And Fellows Of Harvard College | Treatment of neurological disorders using huperzine |
PL2540297T3 (pl) | 2008-11-19 | 2015-12-31 | Forum Pharmaceuticals Inc | Leczenie zaburzeń funkcji poznawczych(R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidem i jego farmaceutyczne dopuszczalnymi solami |
CN102573848A (zh) * | 2009-04-24 | 2012-07-11 | 济州大学校产学协力团 | 含有去甲加兰他敏化合物作为活性成分的用于预防和治疗脱发症的组合物 |
BRPI1014793A2 (pt) * | 2009-05-11 | 2016-04-05 | Envivo Pharmaceuticals Inc | tratamento de distúrbios de cognição com determinados receptores de ácido alfa-7-nicotínico em combinação com inibidores de acetil-colinesterase |
US20110015154A1 (en) * | 2009-07-20 | 2011-01-20 | Kellermann Gottfried H | Supporting acetylcholine function |
US20110098265A1 (en) * | 2009-10-28 | 2011-04-28 | Neuroscience, Inc. | Methods for reducing cravings and impulses associated with addictive and compulsive behaviors |
BR112012019923A2 (pt) | 2010-02-09 | 2016-08-09 | Univ Johns Hopkins | métodos e composições para melhorar a função cognitiva |
PL3029039T3 (pl) | 2010-05-17 | 2018-04-30 | Forum Pharmaceuticals Inc. | Formulacje farmaceutyczne zawierające postacie krystaliczne jednowodnego chlorowodorku (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu |
WO2011151359A1 (en) | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative |
EP2640378A4 (en) * | 2010-11-18 | 2014-05-21 | Envivo Pharmaceuticals Inc | INFLAMMATION TREATMENT WITH CERTAIN NICOTINIC ACID ALPHA-7 RECEPTOR AGONISTS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS |
AU2013259871A1 (en) | 2012-05-08 | 2014-11-20 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
EP2968220B1 (en) | 2013-03-15 | 2021-05-05 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
EP3265127B1 (en) | 2015-03-02 | 2024-02-21 | Corcept Therapeutics, Inc. | Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor |
CN107810002B (zh) | 2015-05-22 | 2021-01-05 | 艾吉因生物股份有限公司 | 左乙拉西坦的延时释放药物组合物 |
US11045482B2 (en) | 2017-03-09 | 2021-06-29 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors |
CN109200051A (zh) * | 2017-07-03 | 2019-01-15 | 南京和博生物医药有限公司 | 石杉碱甲及其类似物作为治疗炎症性疾病药物的用途 |
WO2023070351A1 (zh) * | 2021-10-27 | 2023-05-04 | 香港理工大学 | 通过抑制乙酰胆碱酯酶来预防和治疗骨关节疾病 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US661509A (en) * | 1900-09-04 | 1900-11-13 | John S Fogg | Traveler's hat-conformer. |
US5360811A (en) * | 1990-03-13 | 1994-11-01 | Hoechst-Roussel Pharmaceuticals Incorporated | 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents |
DK0584185T3 (da) * | 1991-05-14 | 2000-02-07 | Ernir Snorrason | Behandling af træthedssyndrom med cholinesteraseinhibitorer |
-
1996
- 1996-03-29 GB GBGB9606736.8A patent/GB9606736D0/en active Pending
-
1997
- 1997-02-19 AU AU21059/97A patent/AU2105997A/en not_active Abandoned
- 1997-02-19 WO PCT/IS1997/000001 patent/WO1997029750A1/en active IP Right Grant
- 1997-02-19 DK DK97906339T patent/DK0918523T3/da active
- 1997-02-19 DE DE69718915T patent/DE69718915T2/de not_active Expired - Fee Related
- 1997-02-19 AT AT97906339T patent/ATE232102T1/de not_active IP Right Cessation
- 1997-02-19 US US09/125,306 patent/US6358941B1/en not_active Expired - Fee Related
- 1997-02-19 ES ES97906339T patent/ES2192667T3/es not_active Expired - Lifetime
- 1997-02-19 CA CA002251114A patent/CA2251114C/en not_active Expired - Fee Related
- 1997-02-19 EP EP97906339A patent/EP0918523B1/en not_active Expired - Lifetime
-
1999
- 1999-12-02 HK HK99105614A patent/HK1020535A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69718915D1 (de) | 2003-03-13 |
GB9606736D0 (en) | 1996-06-05 |
ATE232102T1 (de) | 2003-02-15 |
DK0918523T3 (da) | 2003-05-26 |
DE69718915T2 (de) | 2003-12-11 |
HK1020535A1 (en) | 2000-05-12 |
AU2105997A (en) | 1997-09-02 |
CA2251114A1 (en) | 1997-08-21 |
EP0918523A1 (en) | 1999-06-02 |
EP0918523B1 (en) | 2003-02-05 |
CA2251114C (en) | 2007-10-02 |
US6358941B1 (en) | 2002-03-19 |
WO1997029750A1 (en) | 1997-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2192667T3 (es) | Tratamiento de los trastornos de la artritis, artritis reumatica y manifestaciones asociadas con los trastornos reumaticos. | |
MD809C2 (ro) | (-)-Enantiomer cis-4-amino-1-(2-hidroximetil -1,3-oxatiolan-5-il)-(1H)-pirimidin-2-on sau sarea lui, sau esterul lui, sau sarea esterului lui, amestec de (-)-enantiomer şi (Ş)-enantiomer, procedeu de obţinere a lor, compoziţie antivirotică şi procedeu de tratament al mamiferelor, inclusiv al omului, ce suferă de infecţii virotice sau sunt susceptibile faţă de aceste infecţii | |
MX163955B (es) | Composicion farmaceutica de dihidrocodeina e ibuprofen | |
TR200001982T2 (tr) | Farmasötik vurulu salınımlı oral dozaj şekli. | |
ES2177780T3 (es) | Medicamentos para el tratamiento de enfermedades autoinmunes usando interferon tau. | |
DK1126828T3 (da) | Oral indgivelse af adenosin-analoger | |
LU90987I2 (fr) | Copaxone et ses dérivés pharmaceutiquement acceptables | |
ES8704443A1 (es) | Un procedimiento para la preparacion de derivados sustituidos ester benzoato de 3-hidroximorfinanos. | |
ATE209038T1 (de) | Pharmazeutisches präparat, das heparin, heparinfragmente oder -derivate in kombination mit glycerinestern enthält | |
NZ240230A (en) | Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof | |
NO981436L (no) | Farmas÷ytiske angiostatiske dipeptidsammensetninger og anvendelse derav | |
BE902874A (fr) | Compositions therapeutiques et procede pour le traitement ou la prevention des maladies provoquees par le paf-acether | |
EE04606B1 (et) | H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks | |
DK446684A (da) | Farmaceutisk middel indeholdende et renset, afgiftet endotoksin i kombination med en pyridinoploeselig ekstrakt af en mikroorganisme | |
TR199802537T2 (xx) | Peptit t�revleri. | |
KR860000867A (ko) | 급성 방사선 증후군 발현억제 및 패혈증 발현억제의 방법 및 그 조성물 | |
ATE82294T1 (de) | Therapeutische nukleoside. | |
FR2680172B1 (fr) | Nouvelles piperazinylalcoyl-3 dihydro-2,3 4h-benzoxazine-1,3 ones-4 substituees, leur preparation et leur application en therapeutique. | |
PT1007040E (pt) | Utilizacao de fanquinona no tratamento da doenca de alzheimer | |
NO983177L (no) | Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft | |
MD940152A (ro) | Compoziţie farmaceutică pentru tratarea infecţiilor şi bolilor, provocate de virusul hepatitei V (HBV) | |
BG103512A (en) | Substituted pyramidine compounds and their application | |
BG103435A (en) | Lamivudin- and zidovudin-containing pharmaceutical compositions | |
DE69128254D1 (de) | Antihypertensive benzopyran-derivate | |
ES8504774A1 (es) | Procedimiento para preparar derivados de 2-piperacinil-quinazolina |